| Title |
Cost–Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden
|
|---|---|
| Published in |
Diabetes Therapy, September 2014
|
| DOI | 10.1007/s13300-014-0080-0 |
| Pubmed ID | |
| Authors |
Aliasghar A. Kiadaliri, Ulf G. Gerdtham, Bjorn Eliasson, Katarina Steen Carlsson |
| Abstract |
This study aimed to assess the costs and benefits of three alternative second-line treatment strategies for Swedish patients with type 2 diabetes mellitus (T2DM) who fail to reach glycated hemoglobin (HbA1c) ≤ 7% with metformin treatment alone: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and neutral protamine Hagedorn (NPH) insulin. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 16% |
| Student > Bachelor | 6 | 16% |
| Researcher | 6 | 16% |
| Other | 4 | 11% |
| Student > Ph. D. Student | 4 | 11% |
| Other | 5 | 14% |
| Unknown | 6 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 46% |
| Economics, Econometrics and Finance | 5 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 11% |
| Nursing and Health Professions | 2 | 5% |
| Chemical Engineering | 1 | 3% |
| Other | 2 | 5% |
| Unknown | 6 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2018.
All research outputs
#6,942,073
of 22,763,032 outputs
Outputs from Diabetes Therapy
#269
of 1,013 outputs
Outputs of similar age
#71,186
of 243,384 outputs
Outputs of similar age from Diabetes Therapy
#3
of 10 outputs
Altmetric has tracked 22,763,032 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 1,013 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,384 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.